-
NOVEN PHARMACEUTICALS v. WATSON LABORATORIES, INC. et al DC
- 2:11-cv-05997
- D.N.J.
- Judge: Stanley R. Chesler +1
- Filed: 10/13/2011
- Closed: 03/25/2014
- Latest Docket Entry: 03/26/2014
- PACER
- Docket updated daily
1
Plaintiff
2
Defendants
1
Accused
Product
2
Patents-in-Suit
895
Days in
Litigation
-
NOVEN PHARMACEUTICALS v. WATSON LABORATORIES, INC. et al DC
- 2:11-cv-05997
- D.N.J.
- Judge: Stanley R. Chesler +1
- Filed: 10/13/2011
- Closed: 03/25/2014
- Latest Docket Entry: 03/26/2014
- PACER
- Docket updated daily
Cause of Action
Infringement
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
Claim # | Claim Text | Outcome |
---|---|---|
1 |
A composition for topical application of methylphenidate comprising methylphenidate in a flexible, finite system, wherein the methylphenidate is present in a therapeutically effective amount sufficient to achieve substantially zero order kinetics
view more
|
Invalid
Entry 213 |
2 |
The composition according to claim 1, wherein methylphenidate is in the base form.
|
Invalid
Entry 213 |
6 |
The composition according to claim 1, further comprising an adhesive.
|
Invalid
Entry 213 |
7 |
The composition according to claim 6, wherein the adhesive is selected from the group consisting of acrylics, natural and synthetic rubbers, bioadhesives, polysiloxanes, polyacrylates, polyvinylpyrrolidones, vinylpyrrolidone copolymers, styrene
view more
|
Invalid
Entry 213 |
11 |
The composition according to claim 7, wherein the adhesive includes an acrylic which is a nonfunctional or minimally functional polymer.
|
Invalid
Entry 213 |
12 |
The composition according to claim 7, wherein the adhesive includes a polyacrylate which is a non-vinyl acetate containing polymer.
|
Invalid
Entry 213 |
13 |
The composition according to claim 1, wherein the delivery rate to the skin or mucosa is over a period of time of about 12 to about 20 hours.
|
Invalid
Entry 213 |
14 |
The composition according to claim 1, wherein the delivery to the skin or mucosa is over a period of time of about 14 to about 16 hours.
|
Invalid
Entry 213 |
16 |
A method of treating attention deficit disorder and attention deficit/hyperactivity disorder comprising topically administering methylphenidate in a flexible, finite system, wherein the methylphenidate is present in a therapeutically effective
view more
|
Invalid
Entry 213 |
17 |
The method according to claim 16, wherein the acid functional monomers are present in an amount of no more than about 1 wt %.
|
Invalid
Entry 213 |
18 |
A composition for topical application of methylphenidate comprising methylphenidate in a flexible, finite system, wherein the methylphenidate is present in an amount sufficient to permit a therapeutically effective dose in a patient over a total
view more
|
Invalid
Entry 213 |
19 |
The composition according to claim 18, wherein the delivery rate is from about 2.5 mg/24 hours to about 20 mg/24 hours.
|
Invalid
Entry 213 |
20 |
The composition according to claim 19, wherein the therapeutically effective dose is from about 0.05 mg/kg/day to about 1.0 mg/kg/day.
|
Invalid
Entry 213 |
21 |
The composition according to claim 19, wherein the therapeutically effective dose is from about 0.075 mg/kg/day to about 0.3 mg/kg/day.
|
Invalid
Entry 213 |
-
Infringement
Watson Laboratories, Inc. (Connecticut)
- 2 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
47.5 mg63.3 mg94.9 mgMethylphenidate transdermal systems containing methylphenidate 31.6 mg | US 6,210,705 B1 |
1, 2, 6, 7, 11, 12, 13, 14, 16, 17, 18, 19, 20, 21
|
No infringement
Entry 213
|
Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate | US 6,348,211 B1 | All Asserted Claims |
No infringement
Entry 156
|
Watson Pharmaceuticals, Inc.
- 1 Detail
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate | US 6,348,211 B1 | All Asserted Claims |
No infringement
Entry 156
|